Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma

Am J Hematol. 2022 Jun 1;97(6):833-838. doi: 10.1002/ajh.26527. Epub 2022 Mar 21.

Authors

Andrew M Evens^{1

2}, Justin S Brandt², Cody J Peer³, Tyler Yin³, Dale Schaar¹, Faheem Farooq¹, Brett Mozarsky³, William D Figg³, Elad Sharon⁴

Affiliations

¹ Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
² Departments of Medicine and Maternal Fetal Medicine, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
³ Clinical Pharmacology Program, National Cancer Institute, Bethesda, Maryland, USA.
⁴ Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.

No abstract available

MeSH terms

Female
Hodgkin Disease* / drug therapy
Hodgkin Disease* / pathology
Humans
Immunologic Factors
Immunotherapy
Pregnancy

Substances

Immunologic Factors